fenfluramine has been researched along with Schizophrenia in 23 studies
Fenfluramine: A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.
fenfluramine : A secondary amino compound that is 1-phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension.
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study examined the prolactin (PRL), adrenocorticotropin (ACTH) and cortisol responses to the direct DA receptor agonist apomorphine (APO) and the selective 5HT-releasing agent d-fenfluramine (d-FEN) in 20 untreated inpatients with DSM-IV schizophrenia and without a history of suicide attempt, compared to 23 hospitalized healthy controls." | 9.10 | Dopamine and serotonin function in untreated schizophrenia: clinical correlates of the apomorphine and d-fenfluramine tests. ( Bailey, P; Crocq, MA; Duval, F; Macher, JP; Mokrani, MC; Monreal, J; Valdebenito, M, 2003) |
| "We examined the serotonergic system in drug-free inpatients [schizophrenia (n=28) and schizoaffective (n=7)] by administering a challenge dose of oral dl-fenfluramine (fenfluramine) in a controlled angiocatheter study." | 9.09 | The prolactin response to fenfluramine in schizophrenia is associated with negative symptoms. ( Janicak, PG; Javaid, JI; Pandey, GN; Sharma, RP; Singh, V, 1999) |
| "The authors examined the effect of prolonged clozapine treatment on central serotonergic (5-HT) function in schizophrenia." | 7.70 | Neuroendocrine evidence that clozapine's serotonergic antagonism is relevant to its efficacy in treating hallucinations and other positive schizophrenic symptoms. ( Curtis, VA; Jones, H; Lucey, JV; Wright, P, 1998) |
| "D-fenfluramine has been identified as a highly selective serotonin (5-HT) releaser and re-uptake inhibitor." | 6.69 | Prolactin response to D-fenfluramine challenge test as a predictor of treatment response to haloperidol in acute schizophrenia. ( Czobor, P; Horácek, J; Libiger, J; Mohr, P; Motlová, L, 1998) |
| "Risperidone treatment was associated with a significant functional in-vivo 5-HT antagonism similar to clozapine." | 6.69 | Risperidone is associated with blunting of D-fenfluramine evoked serotonergic responses in schizophrenia. ( Curtis, VA; Jones, H; Lucey, JV; Wright, PA, 1998) |
| "D-Fenfluramine was administered to 22 young, acutely ill schizophrenics (11 females and 11 males) after 4 weeks of haloperidol treatment." | 6.69 | Effects of haloperidol treatment on prolactin response to D-fenfluramine challenge in acute schizophrenia. ( Czobor, P; Horácek, J; Libiger, J; Mohr, P; Motlová, L, 1999) |
| "Fenfluramine was administered to eight severely ill schizophrenic patients as an adjunct to neuroleptic drugs in a double-blind, multiple baseline design." | 6.66 | Adverse effects of fenfluramine in treatment refractory schizophrenia. ( Banzett, L; Bowen, LL; Glynn, SM; Hubbard, JW; Liberman, RP; Marshall, BD; Midha, KK; Mintz, J, 1989) |
| "Fenfluramine was administered to 4 treatment-resistant chronic schizophrenic in-patients." | 6.66 | An open clinical trial of fenfluramine in chronic schizophrenia: a pilot study. ( Gadhvi, H; Kolakowska, T; Molyneux, S, 1987) |
| "Rate of weight loss was significantly greater in those taking D-fenfluramine." | 6.66 | A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity. ( Brown, D; Goodall, E; Oxtoby, C; Richards, R; Silverstone, T; Watkinson, G, 1988) |
| "This study examined the prolactin (PRL), adrenocorticotropin (ACTH) and cortisol responses to the direct DA receptor agonist apomorphine (APO) and the selective 5HT-releasing agent d-fenfluramine (d-FEN) in 20 untreated inpatients with DSM-IV schizophrenia and without a history of suicide attempt, compared to 23 hospitalized healthy controls." | 5.10 | Dopamine and serotonin function in untreated schizophrenia: clinical correlates of the apomorphine and d-fenfluramine tests. ( Bailey, P; Crocq, MA; Duval, F; Macher, JP; Mokrani, MC; Monreal, J; Valdebenito, M, 2003) |
| "We examined the serotonergic system in drug-free inpatients [schizophrenia (n=28) and schizoaffective (n=7)] by administering a challenge dose of oral dl-fenfluramine (fenfluramine) in a controlled angiocatheter study." | 5.09 | The prolactin response to fenfluramine in schizophrenia is associated with negative symptoms. ( Janicak, PG; Javaid, JI; Pandey, GN; Sharma, RP; Singh, V, 1999) |
| "We treated 12 chronic schizophrenic inpatients with fenfluramine, an anorexigenic drug that depletes serotonin, to test the hypothesis that the "negative" symptoms of schizophrenia might be related to brain serotonin activity." | 5.05 | Pilot study on the effects of fenfluramine on negative symptoms in twelve schizophrenic inpatients. ( Berger, PA; Stahl, SM; Uhr, SB, 1985) |
| "The authors examined the effect of prolonged clozapine treatment on central serotonergic (5-HT) function in schizophrenia." | 3.70 | Neuroendocrine evidence that clozapine's serotonergic antagonism is relevant to its efficacy in treating hallucinations and other positive schizophrenic symptoms. ( Curtis, VA; Jones, H; Lucey, JV; Wright, P, 1998) |
| "D-fenfluramine has been identified as a highly selective serotonin (5-HT) releaser and re-uptake inhibitor." | 2.69 | Prolactin response to D-fenfluramine challenge test as a predictor of treatment response to haloperidol in acute schizophrenia. ( Czobor, P; Horácek, J; Libiger, J; Mohr, P; Motlová, L, 1998) |
| "Risperidone treatment was associated with a significant functional in-vivo 5-HT antagonism similar to clozapine." | 2.69 | Risperidone is associated with blunting of D-fenfluramine evoked serotonergic responses in schizophrenia. ( Curtis, VA; Jones, H; Lucey, JV; Wright, PA, 1998) |
| "D-Fenfluramine was administered to 22 young, acutely ill schizophrenics (11 females and 11 males) after 4 weeks of haloperidol treatment." | 2.69 | Effects of haloperidol treatment on prolactin response to D-fenfluramine challenge in acute schizophrenia. ( Czobor, P; Horácek, J; Libiger, J; Mohr, P; Motlová, L, 1999) |
| "Fenfluramine was administered to eight severely ill schizophrenic patients as an adjunct to neuroleptic drugs in a double-blind, multiple baseline design." | 2.66 | Adverse effects of fenfluramine in treatment refractory schizophrenia. ( Banzett, L; Bowen, LL; Glynn, SM; Hubbard, JW; Liberman, RP; Marshall, BD; Midha, KK; Mintz, J, 1989) |
| "Fenfluramine was administered to 4 treatment-resistant chronic schizophrenic in-patients." | 2.66 | An open clinical trial of fenfluramine in chronic schizophrenia: a pilot study. ( Gadhvi, H; Kolakowska, T; Molyneux, S, 1987) |
| "Rate of weight loss was significantly greater in those taking D-fenfluramine." | 2.66 | A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity. ( Brown, D; Goodall, E; Oxtoby, C; Richards, R; Silverstone, T; Watkinson, G, 1988) |
| "The olanzapine-treated patients showed a significantly lower maximal DFEN-evoked PRL response and a significantly lower group x time overall PRL release compared with the untreated patient group." | 1.31 | D-fenfluramine-evoked serotonergic responses in olanzapine-treated schizophrenic patients. ( Curtis, VA; Jones, H; Lucey, JV; Pilowsky, LS; Wright, P, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (30.43) | 18.7374 |
| 1990's | 12 (52.17) | 18.2507 |
| 2000's | 4 (17.39) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jones, H | 3 |
| Curtis, VA | 4 |
| Wright, P | 3 |
| Pilowsky, LS | 1 |
| Lucey, JV | 4 |
| Malone, KM | 1 |
| Waternaux, C | 1 |
| Haas, GL | 1 |
| Cooper, TB | 2 |
| Li, S | 1 |
| Mann, JJ | 1 |
| Duval, F | 2 |
| Mokrani, MC | 2 |
| Monreal, J | 1 |
| Bailey, P | 2 |
| Valdebenito, M | 1 |
| Crocq, MA | 2 |
| Macher, JP | 2 |
| Reveley, A | 1 |
| Kerwin, R | 1 |
| Thompson, PA | 1 |
| Maes, M | 1 |
| Meltzer, HY | 1 |
| Abel, KM | 1 |
| O'Keane, V | 1 |
| Murray, RM | 1 |
| Mohr, P | 2 |
| Horácek, J | 2 |
| Motlová, L | 2 |
| Libiger, J | 2 |
| Czobor, P | 2 |
| Wright, PA | 1 |
| Monteleone, P | 1 |
| Tortorella, A | 1 |
| Borriello, R | 1 |
| Cassandro, P | 1 |
| Maj, M | 1 |
| Sharma, RP | 1 |
| Singh, V | 1 |
| Janicak, PG | 1 |
| Javaid, JI | 1 |
| Pandey, GN | 1 |
| Corrêa, H | 1 |
| Trémeau, F | 1 |
| Staner, L | 1 |
| Diep, TS | 1 |
| Lichtenberg, P | 1 |
| Shapira, B | 1 |
| Blacker, M | 1 |
| Gropp, C | 1 |
| Calev, A | 1 |
| Lerer, B | 1 |
| Lemus, CZ | 1 |
| Lieberman, JA | 1 |
| Johns, CA | 1 |
| Mayerhoff, DI | 1 |
| Pollack, S | 1 |
| Novacenko, H | 1 |
| Soper, HV | 1 |
| Elliott, RO | 1 |
| Rejzer, AA | 1 |
| Marshall, BD | 2 |
| Glynn, SM | 1 |
| Midha, KK | 1 |
| Hubbard, JW | 1 |
| Bowen, LL | 1 |
| Banzett, L | 1 |
| Mintz, J | 1 |
| Liberman, RP | 1 |
| Alphs, LD | 1 |
| Lafferman, JA | 1 |
| Ross, L | 1 |
| Bland, W | 1 |
| Levine, J | 1 |
| Kolakowska, T | 1 |
| Gadhvi, H | 1 |
| Molyneux, S | 1 |
| Goodall, E | 1 |
| Oxtoby, C | 1 |
| Richards, R | 1 |
| Watkinson, G | 1 |
| Brown, D | 1 |
| Silverstone, T | 1 |
| Shore, D | 1 |
| Korpi, ER | 1 |
| Bigelow, LB | 1 |
| Zec, RF | 1 |
| Wyatt, RJ | 1 |
| Stahl, SM | 1 |
| Uhr, SB | 1 |
| Berger, PA | 1 |
| Shannon, PJ | 1 |
| Leonard, D | 1 |
| Kidson, MA | 1 |
15 trials available for fenfluramine and Schizophrenia
| Article | Year |
|---|---|
Dopamine and serotonin function in untreated schizophrenia: clinical correlates of the apomorphine and d-fenfluramine tests.
Topics: Adrenocorticotropic Hormone; Adult; Apomorphine; Brief Psychiatric Rating Scale; Diagnosis, Differen | 2003 |
Effect of the placebo control condition in neuroendocrine challenge studies.
Topics: 5-Hydroxytryptophan; Antipsychotic Agents; Apomorphine; Bias; Buspirone; Data Interpretation, Statis | 1994 |
Prolactin response to D-fenfluramine challenge test as a predictor of treatment response to haloperidol in acute schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Brief Psychiatric Rating Scale; Female; Fenfluram | 1998 |
Risperidone is associated with blunting of D-fenfluramine evoked serotonergic responses in schizophrenia.
Topics: Adult; Antipsychotic Agents; Fenfluramine; Humans; Hydrocortisone; Prolactin; Psychiatric Status Rat | 1998 |
Effects of haloperidol treatment on prolactin response to D-fenfluramine challenge in acute schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Female; Fenfluramine; Haloperidol; Humans; Male; Prolact | 1999 |
Prolactin hyperresponsiveness to D-fenfluramine in drug-free schizophrenic patients: a placebo-controlled study.
Topics: Adolescent; Adult; Chronic Disease; Double-Blind Method; Female; Fenfluramine; Humans; Hydrocortison | 1999 |
The prolactin response to fenfluramine in schizophrenia is associated with negative symptoms.
Topics: Administration, Oral; Adult; Brief Psychiatric Rating Scale; Female; Fenfluramine; Humans; Hydrocort | 1999 |
Effect of fenfluramine on mood: a double-blind placebo-controlled trial.
Topics: Adult; Affect; Arousal; Bipolar Disorder; Depressive Disorder; Double-Blind Method; Female; Fenflura | 1992 |
Effects of fenfluramine on neuropsychological and communicative functioning in treatment-refractory schizophrenic patients.
Topics: Adult; Attention; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Drug Administratio | 1990 |
Adverse effects of fenfluramine in treatment refractory schizophrenia.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Female; Fenfluramine; Humans; Male; Middle Age | 1989 |
Fenfluramine treatment of negative symptoms in older schizophrenic inpatients.
Topics: Fenfluramine; Humans; Male; Middle Aged; Schizophrenia | 1989 |
An open clinical trial of fenfluramine in chronic schizophrenia: a pilot study.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combination; F | 1987 |
A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Double-Blind Method; Female; Fenfluramine; Hu | 1988 |
Fenfluramine and chronic schizophrenia.
Topics: Adult; Age Factors; Cerebral Ventricles; Chronic Disease; Clinical Trials as Topic; Double-Blind Met | 1985 |
Pilot study on the effects of fenfluramine on negative symptoms in twelve schizophrenic inpatients.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Fenfluramine; Humans; Male; Middle Aged; Psych | 1985 |
8 other studies available for fenfluramine and Schizophrenia
| Article | Year |
|---|---|
D-fenfluramine-evoked serotonergic responses in olanzapine-treated schizophrenic patients.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Diagnostic and Statistical Manua | 2002 |
Cigarette smoking, suicidal behavior, and serotonin function in major psychiatric disorders.
Topics: Adolescent; Adult; Aged; Comorbidity; Depressive Disorder; Female; Fenfluramine; Humans; Hydrocortis | 2003 |
Effect of clozapine on d-fenfluramine-evoked neuroendocrine responses in schizophrenia and its relationship to clinical improvement.
Topics: Adult; Clozapine; Female; Fenfluramine; Humans; Hydrocortisone; Male; Prolactin; Psychiatric Status | 1995 |
Enhancement of the prolactin response to d-fenfluramine in drug-naive schizophrenic patients.
Topics: Adult; Anxiety Disorders; Brain; Depressive Disorder; Female; Fenfluramine; Guilt; Humans; Hydrocort | 1996 |
Neuroendocrine evidence that clozapine's serotonergic antagonism is relevant to its efficacy in treating hallucinations and other positive schizophrenic symptoms.
Topics: Adult; Antipsychotic Agents; Clozapine; Female; Fenfluramine; Hallucinations; Humans; Male; Prolacti | 1998 |
Serotonergic function and suicidal behavior in schizophrenia.
Topics: Adult; Biomarkers; Female; Fenfluramine; Humans; Male; Middle Aged; Prolactin; Risk Assessment; Schi | 2002 |
Hormonal response to fenfluramine challenges in clozapine-treated schizophrenic patients.
Topics: Administration, Oral; Adult; Brain; Chronic Disease; Clozapine; Female; Fenfluramine; Humans; Male; | 1991 |
Letter: Fenfluramine and psychosis.
Topics: Adult; Depression; Female; Fenfluramine; Humans; Obesity; Psychoses, Substance-Induced; Schizophreni | 1974 |